0001225208-24-000107.txt : 20240102 0001225208-24-000107.hdr.sgml : 20240102 20240102203020 ACCESSION NUMBER: 0001225208-24-000107 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231229 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fitzgerald Joseph Michael CENTRAL INDEX KEY: 0001484186 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24504123 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0508 4 2023-12-29 0000885725 BOSTON SCIENTIFIC CORP BSX 0001484186 Fitzgerald Joseph Michael 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP & Group Pres, Cardiology 0 Common Stock 2023-12-29 4 M 0 58189.0000 16.3100 A 256181.0000 D Common Stock 2023-12-29 4 S 0 81940.0000 57.5000 D 174241.0000 D Common Stock 2024-01-01 4 M 0 21799.0000 0.0000 A 196040.0000 D Common Stock 2024-01-01 4 F 0 10908.0000 57.8100 D 185132.0000 D Common Stock 68004.0000 I By 401(k) Common Stock 4344.0000 I By Child Stock Option (Right to Buy) 16.3100 2023-12-29 2023-12-29 4 M 0 58189.0000 0.0000 D 2025-02-23 Common Stock 58189.0000 0.0000 D Performance Share Units 2024-01-01 4 M 0 21799.0000 0.0000 D 2023-12-31 2023-12-31 Common Stock 21799.0000 0.0000 D The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c). On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. /s/ Susan Thompson, Attorney-in-Fact 2024-01-02